Intended for healthcare professionals

Feature Drug Regulation

Rosiglitazone, marketing, and medical science

BMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c1848 (Published 07 April 2010) Cite this as: BMJ 2010;340:c1848

The Rosiglitazone Debacle: A GP perspective

Most general practitioners learn about advances and changes in
medicines from reading journals and speaking with
pharmaceutical industry representatives. The latter, of
course, should be taken with an appropriate measure of salt.
Over the last three years, it has been interesting listening
to reps either defending Rosiglitazone, suggesting the
'allegations' were spurious and no different to competitors'
products, or the said competitors exploiting the 'debate' to
their own advantage.

The average, seasoned GP, hopefully, only prescribes after
due consideration of the available evidence; and the fact the
machinations, wrangling and vested interests extend to the
very top, should come as no surprise.

Competing interests:
Diabetic Lead GP in Biggar
Health Centre

Competing interests: No competing interests

12 April 2010
David Carvel
GP principal
Biggar Health Centre, South Croft Road, Biggar, Lanarkshire ML12 6BE